The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | Mezigdomide: a novel CELMoD showing promise in the treatment of R/R myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses mezigdomide, a novel cereblon E3 ligase modulator (CELMoD) under investigation in relapsed/refractory (R/R) multiple myeloma (MM). It has shown promise in treating triple-class refractory patients, and those with extramedullary disease. The response and durability of disease control are increased when mezigdomide is combined with other molecules such as dexamethasone, proteasome inhibitors, and antibodies. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK, Janssen, Takeda, Oncopeptides, Celgene/BMS, Karyopharm, Takeda.
